Clinical Trials Search
A Multi-Center Open-Label Phase 1/2 Study of BGB324 in Combination with Erlotinib in Patients with Stage IIIb or Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to test the safety of the study drug BGB324 and see what effects it has on participants and their cancer when given with erlotinib (a drug used to treat some patients with non-small cell lung cancer).
Primary Objective: To explore the safety and tolerability of single agent BGB324 in patients with NSCLC. Secondary Objectives: To explore the safety and tolerability of BGB324 administered in combination with erlotinib in patients with NSCLC. To identify the dose limiting toxicity (DLT) profile of BGB324 administered in combination with erlotinib in this population. To assess the pharmacokinetics of BGB324 and erlotinib and the potential effect of BGB324 on erlotinib.